“We were disappointed both in not finding a clinical efficacy and finding the mortality signal”

In a Charing Cross (CX) roundtable discussion, Peter Schneider (University of California, San Francisco, USA), Sabine Steiner (Vienna, Austria), Mårten Falkenberg (Sahlgrenska University Hospital and the University of Gothenburg, Gothenberg, Sweden) and Koen Deloose (AZ Sint-Blasius Hospital, Dendermonde, Belgium) consider the impact of the SWEDEPAD 2 trial results on updated European Society for Vascular Surgery (ESVS) recommendations on the management of asymptomatic peripheral arterial disease (PAD) and intermittent claudication.